MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.998
-0.092
-4.39%
Opening 13:30 06/22 EDT
OPEN
2.060
PREV CLOSE
2.090
HIGH
2.060
LOW
1.970
VOLUME
270.55K
TURNOVER
--
52 WEEK HIGH
5.29
52 WEEK LOW
1.490
MARKET CAP
88.62M
P/E (TTM)
-1.9008
1D
5D
1M
3M
1Y
5Y
BRIEF-Recro Appoints Laura L. Parks, Ph.D. To Board Of Directors
reuters.com · 6d ago
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOsEXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (...
GlobeNewswire · 6d ago
Significant Insider Selling in Shares of Recro Pharma
MT Newswires · 6d ago
Athyrium Capital Management, LP Buys Recro Pharma Inc
GuruFocus News · 06/15 12:38
Insider Trends: Insider 90-Day Selling Trend Continued at Recro Pharma
MT Newswires · 06/14 16:26
Recro expands capabilities for clinical trial services offerings
Recro Pharma (REPH) has expanded the clinical capabilities of the company’s Clinical Trial Services ((CTS)) offerings.Included among the recently added CTS capabilities are clinical-scale sachet and blister packaging for clinical
Seekingalpha · 06/02 11:54
BRIEF-Recro Expands Capabilities For Growing Clinical Trial Services (CTS) Offerings
reuters.com · 06/02 11:25
Recro Expands Capabilities for Growing Clinical Trial Services Offerings
Recro Pharma, Inc. ((&ldquo, Recro&rdquo, , NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral
Benzinga · 06/02 11:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPH. Analyze the recent business situations of Recro Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPH stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 23.92M
% Owned: 53.95%
Shares Outstanding: 44.35M
TypeInstitutionsShares
Increased
28
2.37M
New
14
4.80M
Decreased
20
1.00M
Sold Out
8
913.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.51%
Pharmaceuticals & Medical Research
-0.48%
Key Executives
Chairman/Independent Director
Wayne Weisman
President/Chief Executive Officer/Director
J. David Enloe
President/Chief Executive Officer/Director
David Enloe
Chief Financial Officer
Ryan Lake
Executive Vice President
Jyrki Mattila
Director
Geraldine Henwood
Independent Director
William Ashton
Independent Director
Michael Berelowitz
Independent Director
Winston Churchill
Independent Director
James Miller
Independent Director
Laura Parks
Independent Director
Bryan Reasons
No Data
About REPH
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPH stock methods without spending real money on the virtual paper trading platform.